| 摘要 |
<p>Disclosed is the use of a Modified Vaccinia Virus Ankara (MVA) for the preparation of a medicament for protecting an animal, including a human, against an antigen or self-protein, wherein the antigen or the self-protein is different from the antigens associated with the MVA and wherein the MVA is a virus that abortively infects the animal including a human, wherein said protecting an animal leads to the development of an immune response against the antigen or self-protein. Also disclosed is the use of an MVA for the preparation of a medicament for the vaccination or treatment of an animal, including a human, wherein the MVA is a virus that abortively infects the animal, including a human, wherein the vaccination or treatment is (i) to induce or enhance the maturation of the immune system provided that the animal is not a neonatal, (ii) to increase the level of factors which activate and/or mobilize dendritic cells or their precursor cells, (iii) to increase the number of dendritic cells or their precursor cells and/or (iv) to increase the production and/or cellular content of an interferon (IFN) or IL-12. (62) Divided Out of 536592</p> |
